Walleye Capital LLC Buys Shares of 300,184 Eyepoint Pharmaceuticals, Inc. $EYPT

Walleye Capital LLC bought a new position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 300,184 shares of the company’s stock, valued at approximately $3,869,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. California State Teachers Retirement System raised its position in Eyepoint Pharmaceuticals by 20.6% in the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after buying an additional 794 shares during the last quarter. RWC Asset Management LLP grew its stake in shares of Eyepoint Pharmaceuticals by 6.4% in the fourth quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock worth $315,000 after acquiring an additional 1,040 shares during the period. MCF Advisors LLC raised its holdings in shares of Eyepoint Pharmaceuticals by 8.3% during the fourth quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock valued at $273,000 after purchasing an additional 1,149 shares during the last quarter. Raymond James Financial Inc. raised its holdings in shares of Eyepoint Pharmaceuticals by 11.0% during the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock valued at $112,000 after purchasing an additional 1,177 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Eyepoint Pharmaceuticals by 51.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after purchasing an additional 1,358 shares during the period. 99.41% of the stock is owned by institutional investors.

Eyepoint Pharmaceuticals Price Performance

Shares of EYPT stock opened at $12.66 on Thursday. Eyepoint Pharmaceuticals, Inc. has a 1 year low of $9.40 and a 1 year high of $19.11. The firm has a fifty day moving average price of $13.21 and a 200-day moving average price of $14.10. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -3.62 and a beta of 1.73.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%.The company had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.35 million. Equities research analysts expect that Eyepoint Pharmaceuticals, Inc. will post -3.31 EPS for the current year.

Analysts Set New Price Targets

EYPT has been the topic of several research reports. Chardan Capital raised their target price on shares of Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Friday, July 17th. Cantor Fitzgerald initiated coverage on Eyepoint Pharmaceuticals in a research report on Wednesday, July 8th. They issued an “overweight” rating and a $47.00 target price on the stock. Royal Bank Of Canada cut their price target on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Finally, Guggenheim reaffirmed a “buy” rating and set a $68.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Eyepoint Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $43.75.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.